Journal
Blood Advances
Publication Date
2-13-2024
Volume
8
Issue
3
First Page
549
Last Page
552
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023011698
Rights and Permissions
Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett NL. Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Adv. 2024 Feb 13;8(3):549-552. doi: 10.1182/bloodadvances.2023011698. © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Epperla, Narendranath; Zhao, Qiuhong; Moyo, Tamara; Watkins, Marcus P; Tavakkoli, Montreh; Bello, Celeste; Torka, Pallawi; Reddy, Nishitha; Thomas, Colin; Annunzio, Kaitlin; Christian, Beth; Barta, Stefan K; Shouse, Geoffrey; Olszewski, Adam J; and Bartlett, Nancy L, "Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: A real-world analysis." Blood Advances. 8, 3. 549 - 552. (2024).
https://digitalcommons.wustl.edu/oa_4/3413
Additional Links
Supplemental material is available for this article at publisher site.
